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Introduction
The human herpesvirus Epstein-Barr virus (EBV) is associated 
with various B cell lymphomas, including Burkitt lymphoma (BL), 
Hodgkin lymphoma (HL), lymphoproliferative disease (LPD) in 
immunocompromised hosts, and diffuse large B cell lymphomas 
(DLBCLs) in AIDS patients and the elderly (1, 2). The great major-
ity of EBV-infected tumor cells have latent infection, which allows 
the virus to persist as a nuclear episome that is replicated once per 
cell cycle using the host cell DNA polymerase (3). At least 3 differ-
ent forms of viral latency, which differ with respect to the number 
of viral genes expressed, can occur in EBV-positive tumor cells (3, 
4). The only type of EBV infection that is sufficient to transform 
primary B cells in vitro into long-term lymphoblastoid cell lines 
(LCLs) is called type III latency; cells with this form of latency 
express each of the 9 latent viral proteins. Although type III laten-
cy is clearly the most transforming form of EBV latency, it is only 
found in tumors of immunosuppressed patients, since it is also the 
most immunogenic form.
Latent membrane protein 1 (LMP1), the major EBV oncopro-
tein, mimics a constitutively active CD40 receptor and interacts 
with cellular TNF receptor–associated factor (TRAF) proteins to 
induce various downstream pathways (including NF-κB, PI3K, and 
STAT3) that promote B cell proliferation and apoptosis resistance 
(5–8). Although LMP1 is essential for the long-term outgrowth of 
EBV-transformed LCLs in vitro in the absence of a feeder layer (9), 
EBV-positive lymphomas in vivo often have more restricted forms 
of viral latency. For example, EBV-positive BLs, which are largely 
driven by MYC translocations, usually express only the EBNA1 
protein (required for latent EBV genome maintenance), in addi-
tion to the virally encoded microRNAs and EBV-encoded small 
nuclear RNAs (EBER) (1, 2, 10, 11). Furthermore, the majority of 
EBV-positive AIDS-related DLBCLs do not express detectable 
LMP1 protein (12). Thus, EBV appears to promote the growth of 
human tumors such as DLBCLs and BLs even in the absence of 
LMP1 expression. However, since EBV cannot replicate in nonpri-
mate cells, it has been difficult to develop small animal models to 
study how EBV infection might drive the development of B cell 
lymphomas in the absence of LMP1 expression.
One of the key factors that likely influences LMP1 expres-
sion in vivo is its comparatively high immunogenicity for T cells, 
which leads to increased targeting of LMP1+ cells by cytotoxic T 
lymphocytes (CTLs) (13). Levels of LMP1 protein within LCLs 
have been found to vary over a 10-fold range, and to cycle over 
time (14–16). Cells with the highest level of LMP1 have enhanced 
MHC class I expression and are preferentially killed by T cells in 
vitro (14). In addition, LMP1 activates CD95 expression, promot-
ing FAS-mediated killing by T cells (17). Moreover, LMP1 induced 
early-onset B cell lymphomas in a recent LMP1 transgenic mouse 
model only when T cell function was inhibited, since LMP1+ B 
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Thus, in order to understand the counterbalancing role(s) of 
LMP1 in lymphoma induction, it is important to study its effects 
in the context of the intact virus, and in the presence and absence 
of T cells that may more efficiently target LMP1+ cells for cytolysis 
or may provide signals that can substitute for its effects on B cells. 
NOD/LtSz-scid/IL2Rγnull (NSG) mice reconstituted with human 
immune cells represent an excellent small-animal model for study-
ing the roles of specific EBV proteins in the development of B cell 
lymphomas in the presence of a host immune response (24–29). 
NSG mice engrafted with both human fetal hematopoietic stem 
cells and thymic tissue [referred to herein as hNSG(thy) mice] sup-
port significant levels of T cell function (30). In previous studies, 
we showed that EBV (B95.8 strain) infection in hNSG(thy) mice 
induces EBV-positive DLBCLs in a subset of infected mice, while 
the rest of the mice successfully control their EBV infection and 
develop long-term (tumor-free) viral latency (26, 27). Further-
more, we found that alteration of T cell function in hNSG(thy) mice 
using the anti-CD3 mAb OKT3 (which initially activates T cells and 
then depletes them) greatly increases the number and size of EBV-
infected lymphomas in this humanized mouse model (27).
Although hNSG(thy) mice provide an excellent model for 
understanding how the host immune response controls EBV infec-
tion and prevents lymphomas, such mice are expensive and tech-
nically difficult to make and require the use of human fetal tissue. 
In addition, since even WT EBV infection results in relatively few 
lymphomas in this model, humanized NSG models that are less 
immunocompetent may be more useful for studying the role of var-
ious EBV genes in the development of EBV-induced lymphomas.
Here, we demonstrated that cord blood cells infected briefly 
in vitro with either WT EBV or the LMP1-deleted EBV mutant 
(referred to herein as LMP1-KO EBV) caused lymphomas when 
injected into NSG mice. However, in contrast to the WT EBV–
induced lymphomas, the LMP1-KO EBV–induced lymphomas 
required the presence of human CD4+ T cells. Furthermore, we 
showed that a CD40-blocking Ab inhibited cord blood lympho-
mas induced by either WT EBV or LMP1-KO EBV. In the more 
immunocompetent hNSG(thy) humanized mouse model, WT 
EBV induced lymphomas more efficiently than LMP1-KO EBV, 
although the latter could establish persistent viral latency. These 
results indicate that T cells can both promote and inhibit EBV-
induced B cell lymphomas, depending on the quality of the T cell 
response and the presence of LMP1 expression. Our findings also 
suggest that CD40-blocking Abs may be a promising approach for 
treating certain types of EBV-induced lymphomas.
Results
LMP1-KO EBV induces cord blood–derived lymphomas in NSG mice. 
To determine whether EBV can induce lymphomas in vivo even 
in the absence of LMP1 expression, we developed a model system 
in which CD34-depeleted human cord blood cells were either 
mock-infected or infected for 1.5 hours in vitro with 30,000 infec-
tious particles of WT or LMP1-KO EBV, then injected i.p. into NSG 
mice. The presence of EBV infection and EBV lymphomas was 
then determined using the same methods described for our previ-
ous studies of EBV infection in hNSG(thy) mice (26). In the cord 
blood model, WT EBV–infected mice generally developed tumor 
symptoms requiring euthanasia 30–40 days after infection.
cells were otherwise eliminated by T cell–mediated killing (13). 
Thus, while LMP1 may promote B cell lymphomas by its CD40-
like signaling effects, it also enhances killing of EBV-infected B 
cells by functional T cells.
The main route by which CD40 signaling is mediated in B 
cells is via contact with activated T lymphocytes that have upregu-
lated expression of CD40 ligand (CD40L) at the cell surface (6). 
It is not known whether activated T cells expressing CD40L can 
substitute for the transforming function(s) of LMP1 in vivo, pro-
vided the T cells cannot efficiently kill the EBV-infected B cells. 
However, cord blood–derived helper T cells have been reported 
to increase the ability of EBV to transform cord blood–derived B 
cells in vitro by 10-fold (18). Interestingly, the ability of periph-
eral blood lymphocytes from healthy EBV-seropositive humans to 
induce EBV-positive B cell lymphomas in SCID mice requires the 
presence of coinjected T cells (19–23), although established LCLs 
can induce lymphomas in SCID mice without T cells.
Figure 1. LMP1-KO EBV–infected human cord blood induces invasive 
lymphomas in NSG mice. Representative H&E-stained LMP1-KO EBV– and 
WT EBV–infected lymphomas invading the pancreas. EBER was detected 
by ISH, and cellular proteins IRF4 and CD20 were detected by IHC. Original 
magnification, ×10 (top row), ×100 (bottom rows).
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tumors have type III latency, RNA was isolated from 
tumor cells, reversed transcribed, and PCR ampli-
fied using primers specific for the type III (Cp pro-
moter) and type I/II (Qp promoter) forms of the 
EBNA transcript. The type III form of the EBNA 
transcript was detected in LMP1-KO EBV–infected 
tumor cells, but the type I/II form was not (Figure 
3B). Although LMP1 has been reported to inhibit 
lytic viral reactivation (31), very few LMP1-KO EBV–
infected (or WT EBV–infected) cord blood lympho-
ma cells expressed the EBV immediate-early lytic 
protein, BZLF1 (data not shown). Both WT EBV– and 
LMP1-KO EBV–infected cord blood cell lymphomas 
were heavily infiltrated by T cells, as assessed by the 
number of cells staining positively for CD3 within 
the tumors (Figure 3A and data not shown).
Both WT EBV– and LMP1-KO EBV–infected cord 
blood lymphomas showed numerous cells staining 
positively for the proliferation marker Ki67 (Figure 
4, A and B). WT EBV– and LMP1-KO EBV–induced 
tumors were also both positive for expression of 
MYC (Figure 4B), which is known to be activated by 
the EBNA2 viral protein. WT EBV– and LMP1-KO 
EBV–induced lymphomas also showed strong stain-
ing for the transcription factor IRF4 (also known as 
MUM-1) (Figure 1 and Figure 4A), a marker for early 
plasma cell differentiation as well as an essential sur-
vival factor both for EBV-transformed LCLs in vitro (32, 33) and for 
activated DLBCLs (34), HLs (35), and multiple myeloma tumors 
in vivo (36). IRF4 is also a surrogate immunohistochemical (IHC) 
marker for the more aggressive “activated B cell” type of DLBCL.
To ensure that lymphomas observed in mice injected with 
the LMP1-KO EBV–infected cord blood cells were free of any 
WT EBV, we performed IHC to detect LMP1 expression on WT 
EBV– versus LMP1-KO EBV–induced lymphomas (Figure 5A). 
As expected, some of the tumor cells in animals given WT EBV–
infected cord blood expressed LMP1, but no LMP1 staining was 
NSG mice injected with LMP1-KO EBV– or WT EBV–infected 
blood developed EBV-positive lymphomas (Figure 1). Both the WT 
EBV– and the LMP1-KO EBV–infected lymphomas were often clear-
ly invasive, and both had phenotypes similar to the activated form 
of human DLBCL. Lymphomas occurred most commonly in the 
pancreas, gallbladder, liver and mesentery. Cord blood infected with 
either WT EBV or LMP1-KO EBV produced B cell lymphomas in the 
majority of injected NSG mice, and resulted in similar EBV loads, 
although WT EBV–infected lymphomas were often (but not always) 
larger than the LMP1-KO EBV–infected lymphomas derived from the 
same cord blood donor (Figure 2 and data not shown). In contrast, 
none of the mock-infected cord blood cell–injected animals devel-
oped lymphomas or had detectable EBV loads (Figure 2 and data not 
shown). Moreover, in mice injected with mock-infected cord blood, 
the human B cells engrafted very poorly and were often undetectable 
at the end of the experiment, whereas the human T cells expanded 
and persisted for more than 4 weeks (data not shown).
Both WT EBV– and LMP1-KO EBV–induced cord blood lym-
phomas expressed the B cell marker CD20 and the viral protein 
EBNA2 (Figure 1, Figure 3A, and data not shown), suggestive of 
type III viral latency. To confirm that LMP1-KO EBV–infected 
Figure 2. WT and LMP1-KO EBV–infected cord blood cells, but not mock-infected cells, 
promote lymphomas in NSG mice. (A) Incidence and percentage of NSG mice developing 
lymphomas after injection with mock-infected, WT EBV–infected, or LMP1-KO EBV–infect-
ed human cord blood. 6 experiments were performed; 2-tailed Fisher exact test was used 
for statistical analysis. (B) EBV plasma viral loads (obtained at the time of euthanasia) in 
mice injected with WT EBV– or LMP1-KO EBV–infected cord blood. Animal plasma from 3 
experiments were used for testing viral loads; Wilcoxon rank-sum test was used for statis-
tical analysis. For the animals with very high plasma viral loads, exact values are shown.
Figure 3. LMP1-KO EBV–infected cord blood lymphomas have type III 
latency and are heavily infiltrated by T cells. (A) An LMP1-KO EBV–infect-
ed cord blood lymphoma invading the pancreas was stained for H&E, EBV 
EBNA2 protein, CD20, and CD3. The lymphoma was EBNA2+ and CD20+ 
and infiltrated by numerous CD3+ T cells. Original magnification, ×40. (B) 
RT-PCR was performed on RNA isolated from 2 different LMP1-KO EBV–
infected tumors to detect Qp- and Cp-derived EBNA transcripts. Mutu I 
(type I latency) and Kem III (type III latency) cells were used as controls.
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pected, given the severe transformation defect of this mutant in 
vitro (9). However, the LMP1-KO mutant can transform B cells in 
vitro with very low efficiency (less than 1% the efficiency of WT 
EBV) when infected cells are grown continuously on a feeder cell 
layer (9). Since T cells are required for the ability of EBV-induced 
lymphomas to form when peripheral blood lymphocytes from EBV-
positive donors are injected into SCID mice (19–22), we hypoth-
esized that T cells may likewise support the growth of LMP1-KO 
EBV–infected cord blood B cells in humanized NSG mice.
To assess this, total cord blood cells or T cell–depleted frac-
tions were infected with WT EBV or LMP1-KO EBV, then injected 
into NSG mice. LMP1-KO EBV–infected cord blood did not induce 
lymphomas when T cells were depleted (Figure 7A). In contrast, 
lymphomas were induced in mice injected with WT EBV–infected 
cord blood, regardless of whether the T cells had been depleted. 
These results suggest that the B cells infected with LMP1-KO EBV, 
but not WT EBV, are dependent on T cell–derived factors for their 
expansion into lymphomas in NSG mice.
CD4+ T cells are required for growth of LMP1-KO EBV–infected, 
but not WT EBV–infected, cord blood lymphomas. To determine 
whether CD4+ T cells are required for the establishment of LMP1-
KO EBV–infected lymphomas in the cord blood model, mice were 
injected with either WT EBV– or LMP1-KO EBV–infected cord 
blood cells, then treated with or without a CD4+ T cell–depleting 
Ab (CD4R1) starting at day 4 after injection. Anti-CD4 treatment 
observed in those given LMP1-KO EBV–infected cells. To further 
confirm the lack of LMP1 gene expression in LMP1-KO tumors, we 
isolated DNA from paraffin-fixed slides of WT EBV– or LMP1-KO 
EBV–induced tumors and performed PCR analysis using primers 
that can amplify either the viral BZLF1 promoter sequences or 
the LMP1 gene; whereas both were amplified using the WT tumor 
DNA, only the BZLF1 promoter sequences could be amplified 
using the LMP1-KO EBV tumor DNA (Figure 5B).
To assess whether LMP1-KO EBV–induced lymphomas are 
clonal or polyclonal, we used IHC to examine the type of Ig light 
chains expressed by B cells in the tumors. As shown in Figure 6, 
some of the larger and more invasive LMP1-KO EBV–induced lym-
phomas (including that shown in Figure 1) were likely monoclonal, 
based on their preferential expression of κ versus λ light chains. 
However, smaller and less invasive LMP1-KO EBV–induced lym-
phomas (including the gallbladder wall lymphoma shown in Fig-
ure 4A) were likely polyclonal, as assessed by the presence of posi-
tive staining for both light chain types within the tumor (data not 
shown). WT EBV– and LMP1-KO EBV–induced lymphomas had a 
similar distribution of monoclonal versus polyclonal tumors and 
an apparent preference for the κ light chain rearrangement (Sup-
plemental Table 1; supplemental material available online with 
this article; doi:10.1172/JCI76357DS1). The finding that some 
LMP1-KO EBV–induced lymphomas were initially polyclonal sug-
gests that at least the smaller tumors are driven largely by EBV 
infection, rather than secondary cellular mutations.
T cells support the development of LMP1-KO EBV–infected cord 
blood lymphomas in NSG mice. The ability of the LMP1-KO EBV–
infected cord blood to induce lymphomas in NSG mice was unex-
Figure 4. LMP1-KO EBV–induced lymphomas are highly proliferative, 
activated DLBCLs that express c-MYC. (A) LMP1-KO EBV–infected B cells 
infiltrating the gall bladder wall expressed EBER, CD20, Ki67, and IRF4. (B) 
Representative LMP1-KO EBV– and WT EBV–infected lymphomas invading 
the pancreas, stained for either Ki67 or c-MYC (purple) and costained with 
CD20 (brown). Original magnification, ×10 (A); ×100 (B).
Figure 5. LMP1-KO EBV–induced lymphomas do not express LMP1. (A) 
EBER ISH and LMP1 IHC staining of representative WT EBV– and LMP1-KO 
EBV–infected cord blood lymphomas. Original magnification, ×20. (B) 
PCR analysis was performed on isolated tumor DNA prepared from 1 WT 
EBV–infected tumor, 2 different LMP1-KO EBV–infected tumors, or water 
control, using primers that amplify the LMP1 gene (L) or the viral BZLF1 
promoter (Z).
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Ab (Figure 8B and data not shown). Thus, CD40 blockade specifi-
cally inhibited outgrowth of EBV-transformed B cells, while not 
preventing viral infection.
WT EBV–infected, but not LMP1-KO EBV–infected, B cells 
express CD40L in the humanized cord blood model. The findings 
that both WT EBV– and LMP1-KO EBV–induced tumors were 
inhibited by the CD40-blocking Ab, yet only the LMP1-KO EBV–
infected tumors were inhibited by T cell depletion, suggested 
that WT EBV–infected B cells may express CD40L and thus not 
depend on T cells as a source of CD40L stimulation. To examine 
this possibility, CD40L expression on the surface of B cells and 
T cells was examined using FACS analysis in tumors and spleens 
isolated from animals injected with WT EBV– or LMP1-KO EBV–
infected cord blood cells. CD40L was expressed on a portion of T 
cells in animals infected with either EBV, but only B cells infected 
with WT EBV expressed CD40L (Figure 9A). Although we did 
not always detect CD40L expression on tumor B cells from WT 
EBV–infected mice (presumably as a function of the changing 
phenotype of tumor B cells as the tumors progressed), when we 
were able to detect CD40L expression on B cells, it was associ-
ated with WT EBV infection; we never saw CD40L on B cells 
from LMP1-KO EBV–infected mice. This result suggests that the 
dependence of LMP1-KO EBV–derived tumors, but not WT EBV–
derived tumors, on coinjected CD4+ T cells is at least partially 
due to the lack of CD40L expression in LMP1-KO EBV–infected B 
cells. Notably, we also found that splenic T cells in EBV-infected, 
but not uninfected, human cord blood–injected mice expressed 
CD40L (Supplemental Figure 1). This result suggests that T cells 
are the source of CD40L that stimulates LMP1-KO EBV–infect-
ed B cell growth, and that T cell activation occurs in response to 
EBV infection. The T cells also typically expressed high levels of 
the B cell growth factor BAFF in both WT EBV– and LMP1-KO 
inhibited the ability of LMP1-KO EBV to establish lymphomas, 
whereas WT EBV successfully established lymphomas even when 
the CD4+ T cells were depleted (Figure 7B). These results con-
firmed that CD4+ T cells support the growth of LMP1-KO EBV–
infected B cells in the humanized cord blood model.
CD40-blocking Ab inhibits both WT EBV– and LMP1-KO 
EBV–induced cord blood lymphomas in NSG mice. A major path-
way by which activated CD4+ T cells induce the proliferation and 
survival of B cells is by providing a source of CD40L to CD40-
expressing B cells (6). Although LMP1 is thought to mimic the 
effect of constitutively active CD40 signaling, a previous in vitro 
study showed that WT EBV was not able to transform B 
cells obtained from patients with hyper-IgM syndrome, 
who have inactivating mutations of the gene encod-
ing CD40L (37). Thus, expression of LMP1 as a result 
of EBV infection may not completely substitute for 
authentic CD40 signaling in B cells.
To determine whether CD40 signaling is required 
for the ability of either WT EBV or LMP1-KO EBV to 
induce cord blood lymphomas in NSG mice, WT EBV– 
and LMP1-KO EBV–infected mice were treated or not 
with the CD40-blocking Ab 2C10R4 (100 μg per ani-
mal injected i.p. 3 times per week, starting 1 day after 
infection). This Ab has been previously shown to block 
CD40 signaling in vitro and to greatly prolong the sur-
vival of pancreatic islet cell allograft transplants in rhe-
sus macaques without significantly affecting peripheral 
B cell numbers (38). Anti-CD40 treatment inhibited the 
development of lymphomas in animals injected with 
LMP1-KO EBV–infected cord blood and also decreased 
the number of lymphomas induced by WT EBV (Figure 
8A). Notably, WT EBV–induced tumors observed in the 
presence of CD40 Ab were very small (data not shown). 
Anti-CD40 treatment did not prevent engraftment of 
human T cells, and both WT EBV and LMP1-KO EBV 
established persistent viral latency in the presence of the 
Figure 6. LMP1-KO EBV–infected cord blood lymphomas can become 
monoclonal. IHC staining using κ- and λ-specific light chain Abs revealed κ 
light chain dominance in an LMP1-KO EBV–infected pancreatic lymphoma 
as well as polyclonality in the spleen tissue from same animal. Original 
magnification, ×10.
Figure 7. CD4+ T cells support the growth of LMP1-KO EBV–induced cord blood 
lymphomas in NSG mice. (A) Incidence and percentage of NSG mice that developed 
lymphomas after injection with WT EBV– or LMP1-KO EBV–infected human cord 
blood in the presence or absence of T cell–depleting treatments. Data were derived by 
combining the results of 2 experiments each with and without T cell depletion and of 4 
nondepletion experiments; 2-tailed Fisher exact test was used for statistical analysis. 
(B) Incidence and percentage of NSG mice developing lymphomas after injection with 
WT EBV– or LMP1-KO EBV–infected human cord blood in the presence or absence of 
CD4+ T cell–depleting Ab (CD4R1). Data were derived by combining the results of 2 
experiments each with and without anti-CD4 Ab and of 4 no-Ab experiments; 2-tailed 
Fisher exact test was used for statistical analysis.
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EBV–infected animals (Figure 9B), which suggests that there may 
be other pathways, in addition to CD40L, by which T cells can 
enhance the growth of EBV-infected B cells.
The LMP1-KO mutant is defective for inducing lymphomas in 
hNSG(thy) mice, but can establish persistent latent infection. Since we 
previously showed that a subset of WT EBV-infected hNSG(thy) 
mice (engrafted with both human fetal HSCs and fetal thymus) 
eventually develop EBV-positive DLBCLs (26, 27), we also exam-
ined the ability of LMP1-KO EBV to induce lymphomas in this 
more immunocompetent humanized mouse model. Whereas 0 
of 9 LMP1-KO EBV–infected hNSG(thy) animals developed lym-
phomas, 8 of 21 of the WT EBV–infected (B95.8 strain) hNSG(thy) 
animals — some of which were historical controls — developed 
lymphomas (Figure 10). This result suggests that WT EBV is more 
transforming than LMP1-KO EBV in this model.
Because it is currently unknown whether LMP1 is required 
for establishment of persistent viral latency in immunocom-
petent humans, we also sought to determine whether LMP1-
KO EBV can establish persistent latent viral infection in the 
hNSG(thy) model. Animals were considered to be persistently 
infected if, when euthanized 30–60 days after infection, they 
had 1 or more of the following: (a) EBER+ cells on paraffin-fixed 
sections of various organs (including spleen, liver, mesentery, 
pancreas, lungs, and gastrointestinal tract); (b) EBNA1+ or 
EBNA2+ cells, detected by IHC of paraffin-fixed tissue; or (c) 
detectable EBV viral load in the blood, determined by quanti-
tative real-time PCR (Q-PCR). The majority of LMP1-KO EBV–
infected hNSG(thy) mice had persistent latent viral infection, 
similar to the number of WT EBV-infected hNSG(thy) animals 
(Figure 10). While both stringent (EBER+ cells without detect-
able EBNA1) and less-stringent (EBNA1+ or EBNA2+) forms of 
viral latency were observed, lytically infected, BZLF1+ cells 
were not detected (Figure 10D). As expected, mock-infected 
hNSG(thy) animals had no evidence of EBV infection in any of 
these 3 assays (data not shown). Together, these results indicate 
that LMP1 expression enhances (and may be required for) the 
ability of EBV to induce DLBCLs in humanized mice when T 
cells are highly functional, but is not required for the ability of 
EBV to establish persistent latent infection.
LMP1-KO EBV can induce lymphomas in hNSG(thy) mice treat-
ed with the anti-CD3 mAb OKT3. Since we found that almost all 
WT EBV–infected hNSG(thy) mice developed very large lympho-
mas when T cell function was altered by treating mice with OKT3, 
which binds to the CD3 complex of T cells, we next examined 
whether LMP1-KO EBV can induce lymphomas in hNSG(thy) 
animals treated with this mAb. Of the LMP1-KO EBV–infected 
hNSG(thy) mice, 3 of 7 treated with OKT3 developed lympho-
mas, compared with 5 of 6 WT EBV–infected hNSG(thy) mice 
treated with OKT3 (Figure 11A). Notably, the lymphomas in 
OKT3-treated hNSG(thy) mice infected with WT EBV were usu-
Figure 8. CD40 signaling supports 
the growth of both WT EBV– and 
LMP1-KO EBV–induced cord blood 
lymphomas in NSG mice. (A) Inci-
dence and percentage of NSG mice 
developing lymphomas after injection 
with WT EBV– or LMP1-KO EBV–infect-
ed human cord blood in the presence 
or absence of CD40-blocking Ab. 
Data were derived by combining the 
results of 2 experiments each with and 
without anti-CD40 Ab and of 4 no-Ab 
experiments; 2-tailed Fisher exact test 
was used for statistical analysis. (B) A 
peripancreatic granuloma-like lesion in 
a NSG mouse injected with WT EBV–
infected cord blood and treated with 
CD40-blocking Ab, stained for EBER, 
EBNA2, LMP1, CD3, and κ light chain. 
EBV-infected B cells were surrounded 
by T cells. Original magnification, ×40.
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ally much larger than those induced by LMP1-KO EBV (data not 
shown). The LMP1-KO EBV–induced lymphomas in OKT3-treat-
ed hNSG(thy) mice had phenotypes similar to activated human 
DLBCLs, expressed CD20 and IRF4 (Figure 11B), and had type 
III latency. Since OKT3 induces both T cell activation (39, 40) 
and eventual clearance of T cells in vivo, its observed ability 
to increase the frequency of lymphomas induced by LMP1-KO 
EBV in hNSG(thy) mice could be due to enhanced growth sig-
nals derived from activated T cells and/or decreased T cell kill-
ing activity. CD3+ T cells infiltrated the lymphomas that formed 
in LMP1-KO EBV–infected hNSG(thy) mice, even when treated 
with OKT3 (Figure 11B).
Some EBV-positive human DLBCLs contain large numbers of 
infiltrating CD4+ T cells. A subset of human DLBCLs (referred to 
as T cell/histiocyte-rich large B cell lymphomas) are infiltrated by 
high numbers of T cells (41). Since our results in the humanized 
cord blood model suggested that CD4+ T cells may sometimes pro-
mote the growth of EBV-positive DLBCLs in humans, we exam-
ined the number of CD4+ T cells in 4 different EBV-positive, AIDS-
related (non–germinal center type) human DLBCLs. Interestingly, 
1 of these DLBCLs, which did not express LMP1, contained a high 
number of infiltrating CD4+ T cells (Supplemental Figure 2). How-
ever, since the other 3 tumors (including 2 LMP1– DLBCLs) did not 
have many CD4+ T cells (data not shown), additional factors, such 
as mutation of the cellular A20 gene (also known as TNFAIP3) 
(12), may also compensate for loss of LMP1 expression in EBV-
infected human DLBCLs.
Discussion
Numerous EBV-positive lymphomas in humans do not detect-
ably express the major EBV oncoprotein, LMP1, yet retain the 
viral genome. Because the EBV genome is lost from cells when 
it does not provide a survival advantage (11), the continued pres-
ence of EBV in LMP1– human tumors indicates that the virus must 
provide a selective advantage to tumor cells, even in the absence 
of LMP1 expression. Furthermore, the fact that LMP1 enhances 
T cell–mediated killing of EBV-infected cells by numerous differ-
ent mechanisms suggests that there is strong selective pressure 
for EBV-positive tumors in humans to shut down LMP1 expres-
sion. However, to our knowledge, the ability of LMP1-deleted 
EBV to cause lymphomas in vivo had not previously been dem-
onstrated. Here, we showed that LMP1-deleted EBV can indeed 
cause lymphomas in humanized NSG mice in a CD4+ T cell– and 
CD40-dependent manner.
Our present results suggest that activated T cells can at least 
partially replace the requirement for LMP1 expression in EBV-
induced lymphomas by providing a source of CD40 signaling. 
Since we also found that LMP1-KO EBV was compromised in its 
ability to cause lymphomas in hNSG(thy) mice, which have func-
tional T cells due to coengrafted human thymic tissue, it appears 
that the growth and survival advantage of LMP1+ (versus LMP1–) 
lymphoma cells may in some cases outweigh the immunostimu-
latory effect of LMP1 expression. We conclude that T cells may 
either promote or inhibit the development of LMP1– lymphomas in 
humans. Indeed, AIDS patients — who often have hyperstimulat-
Figure 9. T cells, but not B cells, from 
LMP1-KO EBV tumors express CD40L, and 
T cells from tumors express high levels of 
BAFF. Cells isolated from tumors or spleens 
of mice injected with LMP1-KO EBV– or WT 
EBV–infected cord blood were stained with 
Abs specific for human CD45, CD19, CD20, 
CD3, CD40L, BAFF, or the respective isotype-
matched negative controls, then analyzed 
by flow cytometry. Samples were gated on 
single cells expressing human CD45, CD19, and 
CD20 (B cells) or CD45 and CD3 (T cells). Black 
shaded histograms show staining for CD40L 
(A) or BAFF (B); dashed gray histograms show 
staining of the same population of cells by 
the isotype control. Percentages denote the 
fraction of CD40L+ or BAFF+ cells above the 
isotype control background.
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with LMP1-KO EBV–infected B cells) as a source for BAFF ligand. 
Finally, the previous reports showing that T cells are required for 
PBLs from seropositive EBV-positive donors to form EBV-positive 
lymphomas in SCID mice are consistent with prior findings that 
EBV-infected memory B cells in healthy donors have type I latency 
and hence do not express LMP1.
Our current finding that CD40-blocking Ab inhibited devel-
opment of both WT EBV– and LMP1-KO EBV–induced cord blood 
lymphomas in NSG mice is surprising, given that LMP1 expres-
sion is thought to mimic the effect of constitutive CD40 signaling 
(5–7). Nevertheless, this result is consistent with a previous report 
showing that WT EBV cannot induce in vitro transformation of B 
cells obtained from patients with the hyper-IgM syndrome who 
have CD40 ligand mutations (37). Thus, LMP1 does not complete-
ly replace the need for authentic CD40 signaling in EBV-infected 
B cells. Since CD40 signaling has been previously reported to 
induce LMP1 expression in an EBV-positive Hodgkin lymphoma 
cell line with type I latency (47), it is possible that CD40 signaling 
also increases LMP1 expression in the cord blood model. Previ-
ously, EBV infection was shown to induce expression of CD40L 
on EBV-infected B cells in vitro (37). Here, we showed that CD40L 
induction on EBV-infected B cells in vivo in the cord blood human-
ized mouse model required LMP1 expression. In contrast, T cells 
expressed CD40L in animals infected with either EBV, but not 
ed, yet functionally deficient, T cells (42) — often develop LMP1– 
DLBCLs (12). CD40L incorporated into HIV virions (previously 
shown to activate CD40 signaling in B cells; ref. 43) may provide 
another source of CD40 signaling to LMP1– EBV-positive lympho-
mas in AIDS patients.
The same LMP1-KO EBV used in the current in vivo studies 
was previously shown to transform B cells with very low efficien-
cy in vitro (approximately 1% that obtained with WT EBV) in the 
presence of a continuously provided feeder layer (9), although the 
LMP1-KO EBV–infected B cells were unable to form lymphomas 
when injected into SCID mice (9). Our present results suggest that 
CD4+ T cells allow LMP1-KO EBV–infected B cells to survive in 
humanized mice, at least in part, by providing a source of CD40 
signaling. In addition, T cells may provide various additional 
growth factors, cytokines, and signaling ligands essential for the 
survival and growth of LMP1-KO EBV–infected B cells in NSG 
mice. One such factor may be BAFF ligand, since peripheral B cells 
require BAFF for their survival and proliferation (44), and mouse 
BAFF ligand does not induce signaling through the human BAFF 
receptor (45). Consistent with this, we found that tumor-associ-
ated T cells expressed very high BAFF levels (Figure 9B). Inter-
estingly, since transgenic expression of the gene encoding LMP1 
in mice induces expression of BAFF ligand on B cells (46), WT 
EBV–infected B cells may be less dependent on T cells (compared 
Figure 10. LMP1-KO EBV cannot induce lymphomas in highly immunocompetent hNSG(thy) mice, but can establish long-term viral latency. (A and B) 
Incidence and percentage of LMP1-KO EBV– and WT EBV–infected hNSG(thy) mice that developed lymphomas (A) or latent EBV infection (B). Data were 
combined from 4 experiments; 2-tailed Fisher exact test was used for statistical analysis. (C) The spleen of an LMP1-KO EBV–infected hNSG(thy) mice was 
stained with CD20 or anti-EBNA1 Ab. A small fraction of CD20+ B lymphocytes harbored EBV infection, consistent with viral latency. This animal also had a 
detectable viral load in the blood at the time of euthanasia. (D) Spleens from 2 LMP1-KO EBV–infected hNSG(thy) mice subjected to EBER ISH and IHC for 
EBNA1, EBNA2, and BZLF1. Original magnification, ×40 (C); ×100 (D).
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
3 1 2 jci.org   Volume 125   Number 1   January 2015
inhibiting T cell–mediated killing. It will be important to deter-
mine whether EBV-induced lymphoma cells in this model, and 
in humans, express high levels of the T cell–inhibitory ligands 
programmed death–ligand 1 (PD-L1) and PD-L2. If so, blockade 
of programmed cell death protein 1 (PD1) signaling (51) may be a 
particularly efficacious approach for treating EBV-positive tumors, 
which express virally encoded antigens that should be easily rec-
ognized by functional T cells.
Finally, given our finding that a CD40-blocking Ab inhibited 
the ability of both WT EBV and LMP1-KO EBV to induce cord blood 
lymphomas in NSG mice, it is tempting to speculate that blockade 
of CD40 signaling may be useful for treating certain forms of EBV-
induced lymphomas in humans. A CD40-blocking Ab is already 
being tested in human subjects for potential use as an immuno-
suppressive agent to prevent organ rejection in transplant patients. 
Although CD40L-blocking Abs proved to be toxic in humans 
because of unexpected thromboembolic effects (due to CD40L 
expression on platelets), to date, CD40 receptor-blocking Abs have 
not been found to have similar toxicity in humans (52, 53). Never-
theless, since CD40-blocking Abs are predicted to be immunosup-
pressive, they might be most useful for inhibiting the development 
of EBV-induced lymphomas in organ transplant patients, while 
simultaneously preventing organ rejection. It will be important in 
future studies to determine whether CD40 receptor-blocking Abs 
not only prevent the development of EBV-induced lymphomas, but 
also cause regression of established lymphomas.
Methods
EBVs. A WT (B95-8 strain) EBV bacmid p2089 (EB14), which express-
es GFP and a hygromycin B resistance gene, was constructed using 
bacterial artificial chromosome technology as described previously 
(54) and was a gift from H.-J. Delecluse (Deutsches Krebsforschungs-
zentrum, Heidelberg, Germany). The LMP1-KO EBV, missing amino 
acids 1–384 (originally called ΔLMP1), was derived by mutagenesis of 
the p2089 bacmid as previously described (9) and was a gift from W. 
Hammerschmidt (Helmholtz Zentrum München-Haematologikum, 
München, Germany).
Humanized NSG mice. Immunodeficient NSG (NOD/LtSz-
scid/IL2Rγnull) mice were purchased from Jackson Labs (catalog no. 
005557). hNSG(thy) mice, which are engrafted both with purified 
in uninfected cord blood–injected animals. This finding helps to 
explain why LMP1-KO EBV, but not WT EBV, required coinjected 
T cells to form B cell lymphomas in cord blood humanized mice. 
While it remains possible that the results of anti-CD40 treatment 
experiment were due to depletion of B cells by this mAb, the same 
Ab used in these studies was not found to significantly deplete B 
cells in a primate model (38).
The creation of an animal model in which LMP1-deleted 
EBV causes lymphomas should be highly useful for examining 
the transforming functions of other latent EBV genes (and viral 
microRNAs) in this process. The EBV LMP2A protein, which 
mimics the effects of constitutively active B cell receptor (BCR) 
(3), may play an essential role in promoting the development of 
LMP1-KO EBV lymphomas. Like LMP1, LMP2A activates key cell 
survival signaling pathways, including the PI3K/AKT pathway 
(48). The highly proliferative nature of the LMP1-KO lymphomas 
(indicated by their high level of Ki67 expression) may also require 
expression of the EBV EBNA2 protein, which mimics the effect of 
constitutively activated Notch signaling (3). The EBV-encoded 
protein EBNA3C, which inhibits expression of the cell cycle inhibi-
tor p16 (49), may also promote proliferation of the LMP1-KO EBV– 
infected cells. Notably, EBNA3C was also recently shown to stabi-
lize the IRF4 protein in EBV-infected B cells (32), and we found that 
the LMP1-KO EBV–induced lymphomas expressed a high level of 
IRF4. IRF4 is not only an essential growth and survival factor for 
activated human DLBCLs (34), but is also required for survival of 
EBV-transformed LCLs in vitro (32, 33). T cell–derived CD40 sig-
naling may also help to induce IRF4 expression in LMP1-KO EBV–
induced lymphomas (35). Finally, the viral encoded microRNAs 
(a portion of which are expressed by the B95.8 strain of EBV) 
were recently shown to promote the survival of BLs by inhibiting 
apoptosis (11), and likely contribute to the survival of LMP1-KO 
EBV–induced lymphomas.
The failure of the T cells to control EBV-driven lymphomas 
in cord blood–injected NSG mice may partially reflect the imma-
turity of cord blood–derived T cells, as well as the absence of 
EBV-directed memory T cells. Nevertheless, T cell lines directed 
against EBV antigens, which are capable of killing EBV-infected 
B cells, can be obtained from cord blood in vitro (50). Thus, EBV-
infected lymphoma cells may also have mechanisms for actively 
Figure 11. LMP1-KO EBV can induce lymphomas in 
a subset of hNSG(thy) mice treated with the T cell 
receptor Ab OKT3. (A) Incidence and percentage of 
LMP1-KO EBV– and WT EBV–infected hNSG(thy) mice 
that developed lymphomas when treated with OKT3 
Ab. Data were combined from 2 experiments; 2-tailed 
Fisher exact test was used for statistical analysis. (B) 
An LMP1-KO EBV–infected lymphoma invading the 
liver in an OKT3-treated infected hNSG(thy) mouse 
was stained for H&E, costained for EBNA2 (purple) and 
CD20 (red), or costained for CD3 (red) and IRF4 (purple). 
Even with OKT3 treatment, IRF4+ EBV-infected lym-
phoma cells were infiltrated by CD3+ T cells. Neoplastic 
cells coexpressed EBNA2 and CD20, which indicated 
that they are B lymphocytes with type III latency. Origi-
nal magnification, ×100.
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mine whether animals had persistent EBV infection and/or EBV-positive 
lymphomas and to assess the viral protein expression pattern. Analysis 
performed for all animals included H&E staining and IHC staining using 
Abs directed against CD20 (B cell marker), CD3 (T cell marker), and EBV 
proteins EBNA1, EBNA2, LMP1, and BZLF1. In some animals, EBER ISH 
studies were performed using the PNA ISH Detection Kit (DakoCytoma-
tion) according to the manufacturer’s protocol, as previously described 
(26). In some animals, DNA was isolated from paraffin-fixed slides using 
the QIAamp DNA FFPE Tissue Kit (Qiagen, catalog no. 56404) and then 
PCR amplified using primers specific for the EBV LMP1 gene (left, AGT-
CATCGTGGTGGTGTTCA; right, TTACCACACCCCCACTTTTC; 
291 bp) or BZLF1 gene promoter (left, ACCAGCCTCCTCTGTGATGT; 
right, TTTGGACGAACTGACCACAA; 298 bp) to confirm that LMP1-
KO EBV–induced tumors were not contaminated by WT EBV. PCR 
was performed in 50 μl reaction volume containing 0.2 μmol/l primers 
and 1 U Taq DNA polymerase, under the following conditions: 95°C for 
2 minutes; 30 cycles of 95°C for 30 seconds, 58°C for 30 seconds, and 
72°C for 40 seconds; 72°C for 5 minutes. PCR products were visualized 
with ethidium bromide on 1% agarose gel. In some animals, RNA was 
isolated from paraffin-fixed tumor slides using the FFPE RNA Purifica-
tion Kit (NORGEN Biotek Corp., catalog no. 25300), then reversed tran-
scribed using the Reverse Transcription System Kit (Promega, catalog 
no. A3500). cDNA was then amplified using primers that specifically 
detect the EBV Cp-derived EBNA1 transcript (TGGCGTGTGACGTG-
GTGTAA and CATGATTCACACTTAAAGGA) or the Qp-derived 
transcript (GTGCGCTACCGGATGGCG and CATGATTCACACTTA-
AAGGA). GAPDH primers were GGAAGGTGAAGGTCGGAGTCA and 
ATGGGTGGAATCATTGGAACA.
Anti-CD40, anti-CD3, and anti-CD4 Ab treatment. The anti-CD3 
Ab OKT3 was purchased from Imgenex. Mice received 2 μg/d OKT3 
starting 1 day after EBV infection and continuing for 6 days per week 
(alternating i.p. and i.v. route) until the time of euthanasia. The block-
ing anti-CD40 Ab 2C10R4 was obtained through the NIH Nonhuman 
Primate Reagent Resource. This rhesus recombinant (chimeric) form 
of the previously described Ab 2C10 blocks both human and rhesus 
CD40 signaling without inducing CD40 stimulation or causing B cell 
killing (38). Mice were given Ab injections (100 μg i.p.) 3 times week-
ly, starting 1 day after cord blood injection. The anti-CD4 depleting 
Ab CD4R1 was obtained from the NIH Nonhuman Primate Reagent 
Resource. Mice were given Ab injections (100 μg i.p.) 3 times weekly, 
starting day 4 after cord blood injection.
IHC. Formalin-fixed, paraffin-embedded tissue sections were 
deparaffinized and then examined by IHC as previously described 
(26, 27). Abs used are listed in Table 1. IHC staining of CD4 (clone 
4B12, dilution 1:80; Leica Microsystems) was accomplished using the 
Bond III Autostainer (Leica Microsystems). Formalin-fixed, paraffin-
embedded tissue microarray (TMA) sections were first baked and 
deparaffinized. Antigen retrieval was followed by heating the slides 
in Bond Epitope Retrieval Solution 2 (ER2) (Leica Microsystems) at 
99°C–100°C for 30 minutes. Sections were then subjected to sequen-
tial incubation with the endogenous peroxidase block for 5 minutes, 
primary Ab for 25 minutes, post-primary (equivalent to secondary Ab) 
for 15 minutes, polymer (equivalent to tertiary Ab) for 25 minutes, 
diaminobenzidine (DAB) for 10 minutes, and hematoxylin (Bond 
Polymer Define Detection; Leica Microsystems) for 5 minutes. Finally, 
sections were dehydrated in 100% ethanol and mounted in Cytoseal 
XYL (Richard-Allan Scientific).
human CD34+ cells isolated from fetal liver and with human fetal thymus 
(obtained from the same donor), were derived as previously described 
(26, 30). Alternatively, commercially purchased CD34-depleted human 
cord blood mononuclear cells (AllCells LLC, catalog no. CB117) were 
mock-infected or infected with WT EBV or LMP1-KO EBV in vitro for 
1.5 hours, after which 12 × 106–25 × 106 cells were injected i.p. into 3- to 
5-week-old NSG mice. Both WT EBV– and LMP1-KO EBV–infected ani-
mals were included in all cord blood experiments so that results could be 
compared using the same sets of cord blood. In some experiments, the 
cord blood was depleted of T cells using pan–T cell isolation kit (Miltenyi 
Biotec Inc., catalog no. 130-096-535), or B cells were positively selected 
using B cell isolation kit (Miltenyi Biotec Inc., catalog no. 130-093-660), 
prior to EBV infection (or mock infection). Since both manipulations 
gave similar results in terms of tumor development, they were combined 
when calculating the effect of T cell depletion on the ability of WT EBV 
versus LMP1-KO EBV to induce cord blood lymphomas in NSG mice.
Production of infectious virus. Infectious viral particles were pro-
duced from 293 cell lines stably infected with WT EBV or LMP1-KO 
EBV after transfection with EBV BZLF1 and GP110 expression vectors 
as previously described (26). EBV was titered on Raji cells using the 
Green Raji cell assay as previously described (26).
EBV infection of mice. hNSG(thy) mice were injected i.p. with 
30,000 infectious particles of WT EBV or LMP1-KO EBV (diluted 
in PBS; final volume, 200 μl) approximately 10 weeks after engraft-
ment of human cells. In the cord blood experiments, cord blood was 
mock-infected or infected with 30,000 IU WT EBV or LMP1-KO EBV 
for 1.5 hours in vitro, then injected i.p. into NSG mice (diluted in PBS; 
final volume, 200 μl). Mice were sacrificed at day 60 after infection 
in hNSG(thy) mice, unless they developed symptoms requiring eutha-
nasia earlier. In the EBV-infected cord blood animal experiments, as 
soon as 1 or more of the EBV-infected animals needed to be eutha-
nized (generally around 30–40 days after infection), the rest of the 
infected (or mock-infected) animals of that particular donor experi-
ment were also sacrificed, such that the frequency of WT EBV– and 
LMP1-KO EBV–infected tumors could be compared at similar time 
points after infection and in cells derived from the same donor.
Analysis of EBV infection and tumors. After euthanasia, multiple dif-
ferent organs (including the lungs, transplanted thymus, spleen, pan-
creas, liver, gall bladder, mesenteric fat, and abdominal lymph nodes) 
were formalin fixed, then examined using various techniques to deter-
Table 1. Abs used for IHC
Ab Clone Source Dilution
CD20 H1 BD Biosciences — Pharmingen 1:600
CD3 Polyclonal DakoCytomation 1:200
LMP1 CS.1-4 DakoCytomation 1:600
EBNA1 EB14 Gift of R.R. BurgessA 1:100
EBNA2 PE2 Leica Microsystems 1:100
BZLF1 BZ1 Santa Cruz Biotechnology Inc. 1:200
κ light chain L1C1 Imgenex 1:100
λ light chain ICO106 Imgenex 1:100
Ki67 Ki67 Santa Cruz Biotechnology Inc. 1:100
IRF4 MUM1p Santa Cruz Biotechnology Inc. 1:50
c-MYC Y69 Abcam Inc. 1:50
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formation comparison, the P value was calculated using a 2-tailed 
Fisher exact test. For viral load comparison, the P value was calculated 
using the Wilcoxon rank-sum test. A P value less than 0.05 was con-
sidered significant.
Study approval. All animal experiments were approved by the 
University of Wisconsin–Madison IACUC and conducted in accor-
dance with the NIH Guide for the Care and Use of Laboratory Animals. 
For human AIDS-related lymphomas, cases were collected from the 
Department of Pathology and Laboratory Medicine of Weill Cornell 
Medical College. All human samples, obtained with IRB and biospeci-
men use approval, were residual cases after diagnosis.
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Q-PCR to measure EBV viral load in plasma. EBV viral load in 
plasma samples was measured using TaqMan Q-PCR technology 
with primers targeting the EBV genome (55). DNA was extracted 
using High Pure Viral Nucleic Acid Kit (Roche) on 200 μl plasma 
each, except when less volume was available and the calculated result 
was extrapolated accordingly. DNA was eluted in 50 μl nuclease-free 
water, and Q-PCR targeting the EBV BamH1W segment was done in 
almost duplicate (5 μl versus 10 μl input DNA). TaqMan Exogenous 
Internal Positive Control (IPC) was spiked before DNA extraction and 
quantified in the same well, thus serving as a marker of the efficacy of 
extraction and amplification.
FACS analysis. Spleen or tumor tissues were mechanically dis-
sected using a syringe hub, then filtered through a 70-μM cell strainer 
(Fisher Scientific). Cells were spun down, washed in PBS, and then 
diluted into PBS at a concentration of 2 × 106–4 × 106 cells/ml. Cells 
were stained with the following Abs (all from Biolegend): APC-con-
jugated CD45 (catalog no. 304011), BV510-conjugated CD3 (catalog 
no. 317332), FITC-conjugated CD19 (catalog no. 302206), FITC-con-
jugated CD20 (catalog no. 302304), PE-conjugated CD40L (catalog 
no. 310806), and PE-conjugated CD257 (BAFF) (catalog no. 318606). 
Appropriate isotype controls were used in each case. Ab staining was 
analyzed using a LSR II BD flow cytometer.
Statistics. Mstat Software (http://mcardle.wisc.edu/mstat/down-
load/index.html) was used to statistically analyze the data. For tumor 
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